Quantcast

Latest AstraZeneca Stories

2014-06-04 12:28:56

TUCSON, Ariz., June 4, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group and MedImmune, the global biologics research and development arm of AstraZeneca, today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only...

2014-06-03 12:39:42

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The Prostate Cancer Therapeutics Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/treatments/prostate_cancer_therapeutics_market_2013_2023.html Report DetailsProstate cancer therapeutics - assess products, developments, and revenue prospectsHow are the leading segments in the prostate cancer therapeutics market performing? Visiongain's new report shows you their prospects to 2023....

2014-06-03 12:37:54

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Asthma and COPD Therapies: World Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/diseases/asthma/asthma_copd_therapies.html Report DetailsNew study reveals sales potential of this large, expanding marketSee what the future holds for asthma and COPD therapies. Visiongain's report gives you drug revenue predictions to 2023. You find data, trends, opportunities and commercial...

2014-05-30 12:26:02

MERIDEN, Conn., May 30, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that Astellas Pharma has submitted an application for marketing approval of recombinant influenza HA vaccine ASP7374 (marketed as Flublok® in the United States by Protein Sciences) to the Ministry of Health, Labour and Welfare in Japan for the prevention of influenza. UMN Pharma, which is partnered with Astellas, holds an exclusive license from Protein Sciences for the development and marketing...

2014-05-28 08:32:52

PHILADELPHIA, May 28, 2014 /PRNewswire-USNewswire/ -- Premier Research today announced the appointment of Martin Nicklasson, Ph.D., to its board of directors. http://photos.prnewswire.com/prnvar/20140528/91686 Nicklasson brings to Premier Research a wealth of international experience in the biopharmaceutical sector, both at the executive and at the board level. A native of Sweden with a doctoral degree from the University of Uppsala, Nicklasson held positions in pharmaceutical...

2014-05-27 23:04:17

AgFunder, an online investment crowdfunding platform for agriculture and agtech opportunities, is hosting a webinar for accredited investors interested in aWhere, a cloud-based service delivering hyperlocal weather data and recommendations to farmers around the globe. New York, NY (PRWEB) May 27, 2014 aWhere will be raising a $4 million equity financing round on the investment crowdfunding platform AgFunder. aWhere is a Colorado-based agtech company delivering hyperlocal weather data and...

2014-05-27 16:25:33

DUBLIN, May 27, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza(®), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes....

2014-05-27 12:23:12

- Contest runs through July for innovative ideas to support the six commitments of The Good Growth Plan WASHINGTON, May 27, 2014 /PRNewswire/ -- Syngenta announced today a contest for creative ideas that will support one or more of the six measurable commitments of The Good Growth Plan. The Good Growth Plan Grant Contest* will award one Grand Prize of $20,000 to help the winner implement the idea. Also, three runners-up will receive $10,000 each for the same purpose. Deadline for submissions...

2014-05-21 08:29:10

CAMBRIDGE, Mass., May 21, 2014 /PRNewswire/ -- Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) Therapeutics(TM), a revolutionary treatment modality to enable the in vivo production of therapeutic proteins, announced today the formation of a Technology Advisory Board. This new Technology Advisory Board will bring together a world-class panel of experts to advise Moderna on building state-of-the-art GMP (Good Manufacturing Practice) manufacturing capabilities to...

2014-05-20 08:31:59

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 20, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding The Chubb Corporation (NYSE: CB), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), AstraZeneca Plc (NYSE: AZN), Mylan, Inc. (NASDAQ: MYL) and Perrigo Co. (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related